Dismissal of Securities Class Action for Arena Pharmaceuticals

Obtained an order dismissing a federal securities class action against Arena Pharmaceuticals and members of its executive management alleging that the company misrepresented the results of a preclinical study involving the company's leading drug candidate.

Related Contacts
Koji Fukumura Partner, San Diego
Ryan Blair Partner, San Diego
Related Practices & Industries

Securities Litigation